Immune Response to Influenza Vaccine in Subjects with B-cell Malignancies Treated with Idelalisib
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Idelalisib (Primary)
- Indications B-cell leukaemia; B-cell lymphoma
- Focus Pharmacodynamics
- Sponsors Gilead Sciences
- 01 Nov 2019 Status changed from recruiting to discontinued.
- 01 Nov 2019 This trial has been discontinued in Czech Republic, according to European Clinical Trials Database.
- 25 Oct 2019 This trial has been discontinued in France, according to European Clinical Trials Database.